Johnson & Johnson Receives CE Mark for ACUVUE OASYS MAX 2-Week Reusable Contact Lens Johnson & Johnson (NYSE: JNJ) announced that it has received CE Marking for ACUVUE OASYS MAX…
Yarrow Bioscience Launches Underwritten Public Offering to Support Autoimmune Thyroid Disease Pipeline Yarrow Bioscience, Inc., a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, has announced…
Kallisio Expands Patient Access Program for Stentra in Head and Neck Cancer Radiation Therapy Kallisio has announced an expanded patient access program designed to help people preparing for radiation therapy…
Mobile Heartbeat Expands Banyan Platform with Private 5G Support for Healthcare Communications Mobile Heartbeat, a provider of clinical communication and collaboration solutions, has announced that its Banyan platform now supports…
IMDS Launches NHanceIT Microcatheter in the U.S. for Complex Coronary Interventions Interventional Medical Device Solutions (IMDS), a specialty catheter company developing purpose-built technologies for complex percutaneous coronary intervention (PCI), chronic…
BioLab Holdings Expands Placental Membrane Portfolio With New Membrane Wrap Amniotic Hydro BioLab Holdings, Inc., a Phoenix-based medical technology company focused on tissue restoration, has expanded its portfolio of placental…
PureTech Health Notes Positive Phase 1 Driving Trial Results for GlyphAllo in Major Depressive Disorder PureTech Health plc (LSE: PRTC), a biotherapeutics company operating through a hub-and-spoke model to translate…
InduPro Publishes Nature Study Defining New Proximity-Based Targets for Cancer Therapeutics InduPro, Inc., a biotechnology company developing novel therapeutics for cancer and autoimmune diseases through protein proximity biology, has announced…
TRIANA Biomedicines Publishes Nature Study Supporting TRI-611 Molecular Glue Therapy for ALK-Positive NSCLC TRIANA Biomedicines, Inc. (TRIANA), a clinical-stage biopharmaceutical company focused on developing molecular glue therapies against difficult-to-drug disease…
Flatiron Health and NCCN Renew Collaboration to Expand Real-World Evidence Research in Oncology Flatiron Health, a leading healthtech company focused on improving cancer care and advancing oncology research through real-world…
Gossamer Bio Announces 1-for-80 Reverse Stock Split to Regain Nasdaq Compliance Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary vascular diseases,…
PhenoNet Completes Enrollment in Phase IIb Trial of PHENOGENE-1A for ALS PhenoNet, Inc., a clinical-stage biotechnology company developing investigational therapies for neurodegenerative diseases, has announced the completion of recruitment and…